Ангиопоэтиноподобный белок 3 типа – новая мишень гиполипидемической терапии

B. V. Pomogaybo; A. E. Filippov

doi:10.34687/2219-8202.JAD.2022.02.0002

Authors

B. V. Pomogaybo ФКУ «Центральный военный клинический госпиталь им. П.В. Мандрыка» Минобороны России, Москва https://orcid.org/0000-0003-0093-0868
A. E. Filippov Санкт-Петербургский государственный университет, Санкт-Петербург

DOI:

https://doi.org/10.34687/2219-8202.JAD.2022.02.0002

Keywords:

atherosclerosis, angiopoietin-like protein type 3, lipid-lowering therapy, evinacumab, vupanorsen, ARO-ANG3

Abstract

Angiopoietin-like protein type 3 regulates the activity of lipoprotein lipase and endothelial lipase, and its inherited deficiency is accompanied by stimulation of lipolysis, combined hypolipidemia and benefits in cardiovascular risk. The pharmacological effect on angiopoietin-like protein 3 is realized through the action of monoclonal antibodies, antisense targeted therapy and direct genome editing and represents a promising way of lipid-lowering therapy, independent of the functioning of low-density lipoprotein receptors and effectively correcting mixed hyperlipidemias.

Downloads

Download data is not yet available.

References

Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Back M et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34): 3259-3260. doi: 10.1093/eurheartj/ehab484.

Kaasenbrood L, Bhatt DL, Dorresteijn JAN, Wilson PWF, D’Agostino RB Sr, Massaro JM et al. Estimated life Expectancy without recurrent cardiovascular events in patients with vascular disease: The SMART-REACH model. J Am Heart Assoc. 2018;7(16):e009217. doi: 10.1161/JAHA.118.009217

McPherson R. 2018 George Lyman Duff Memorian Lecture. Genetics and genomics of coronary artery disease: a decade of progress. Arterioscler Thromb Vasc Biol. 2019;39(10):1925-1937. doi: 10.1161/ATVBAHA.119.311392.

Chen PY, Gao WY, Liou JW, Lin CY, Wu MJ, Yen JH. Angiopoietin-like protein 3 (ANGPTL3) modulates lipoprotein metabolism and dyslipidemia. Int J Mol Sci. 2021;22(14):7310. doi: 10.3390/ijms22147310.

Romeo S, Yin W, Kozlitina J, Pennacchio LA, Boerwinkle E, Hobbs HH et al. Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J Clin Invest. 2009;119(1):70–9. doi: 10.1172/JCI37118.

Musunuru K, Pirrucello JP, Do R, Poloso GM, Guiducci C, Sougnez C et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med. 2010;363(23):2220-7. doi: 10.1056/NEJMoa1002926.

Ono M, Shimizugawa T, Shimamura M, Yoshida K, Noji-Sakikawa C, Ando Y et al. Protein region important for regulation of lipid metabolism in angiopoietin-like 3 (ANGPTL3): ANGPTL3 is cleaved and activated in vivo. J Biol Chem. 2003;278(43):41804–9. doi: 10.1074/jbc.M302861200.

Dewey FE, Gusarova V, Dunbar RL, O'Dushlaine C, Schurmann C, Gottesman O et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N Engl J Med. 2017;377(3):211–221. doi: 10.1056/NEJMoa1612790.

Stitziel NO, Khera AV, Wang X, Bierhals AJ, Vourakis AC, Sperry AE et al. ANGPTL3 deficiency and protection against coronary artery disease. J Am Coll Cardiol. 2017;69(16):2054–2063. doi: 10.1016/j.jacc.2017.02.030.

Chen MC, Hsu BG, Lee CJ, Wang JH. High-serum angiopoietin-like protein 3 levels associated with cardiovascular outcome in patients with coronary artery disease. Int J Hypertens. 2020:2980954. doi: 10.1155/2020/2980954.

Lang W, Frishman WH. Angiopoietin-like 3 protein inhibition: a new frontier in lipid-lowering treatment. Cardiol Rev. 2019;27(4):211-217. doi: 10.1097/CRD.0000000000000258.

Tikka A, Jauhaiainen M. The role of ANGPTL3 in controlling lipoprotein metabolism. Endocrine. 2016;52(2):187–93. doi: 10.1007/s12020-015-0838-9.

Robciuc MR, Maranghi M, Lahikainen A, Rader D, Bensadoun A, Öörni K et al. Angptl3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids. Arterioscler Thromb Vasc Biol. 2013;33(7):1706–13. doi: 10.1161/ATVBAHA.113.301397.

Rosenson RS, Burgess LJ, Ebenbichler CF, Baum SJ, Stroes ESG, Ali S et al. Evinacumab in patients with refractory hypercholesterolemia. N Engl J Med. 2020;383(24):2307–2319. doi: 10.1056/NEJMoa2031049.

Pirillo A, Catapano AL, Norata GD. Monoclonal antibodies in the management of familial hypercholesterolemia: focus on PCSK9 and ANGPTL3 inhibitors. Curr Atheroscler Rep. 2021;23(12):79. doi: 10.1007/s11883-021-00972-x.

Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383(8):711–720. doi: 10.1056/NEJMoa2004215.

Reeskamp LF, Tromp TR, Stroes ESG. The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease? Curr Opin Lipidol. 2020;31(3):140–146. doi: 10.1097/MOL.0000000000000679.

URL: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-add-therapy-patients-genetic-form-severely-high-cholesterol-0 (Дата обращения: 01.01.2022).

Afanasieva O.I., Ezhov M.V., Pokrovsky S.N. Antisense oligonucleotides and therapeutical monoclonal antibodies as a basement for novel biological lipidlowering drugs. Rus J Cardiol. 2018;23(8):99-109. Russian. (Афанасьева О.И., Ежов М.В., Покровский С.Н. Антисмысловые олигонуклеотиды и терапевтические моноклональные антитела — как основа для создания новых поколений биологических липидснижающих препаратов. Рос. кард. журн. 2018; 23 (8): 99–109). doi: 10.15829/1560-4071-2018-8-99-109.

Graham MJ, Lee RG, Brandt TA, Tai LJ, Fu W, Peralta R et al. Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides. N Engl J Med. 2017;377(3):222-232. doi: 10.1056/NEJMoa1701329.

Gaudet D, Karwatowska-Prokopczuk E, Baum SJ, Hurh E, Kingsbury J, Bartlett VJ et al. Vupanorsen, an N-acetyl galactosamineconjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. Eur Heart J. 2020;41(40):3936–3945. doi: 10.1093/eurheartj/ehaa689.

URL : https://clinicaltrials.gov/ct2/show/NCT04516291 (Дата обращения: 01.01.2022).

Nurmohamed NS, Dallinga-Thie GM, Stroes ESG. Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia. Expert Rev Cardiovasc Ther. 2020;18(6):355-361. doi: 10.1080/14779072.2020.1768848.

Watts G, Gladding P, Schwabe C, Scott R, Clifton P, Sullivan D et al. Reduced expression of angiopoietin-like protein 3 via RNA interference with AROANG3 produces prolonged reductions in LDL-C and triglycerides in dyslipidemic patients. Pharm Control Lipids and Lipoproteins. 2020;14(1):599. doi: 10.1016/j.jacl.2020.05.085.

Chadwick AC, Evitt NH, Lv W, Musunuru K. Reduced blood lipid levels with in vivo CRISPR-Cas9 base editing of ANGPTL3. Circulation. 2018;137(9):975–977. doi: 10.1161/CIRCULATIONAHA.117.031335.